Jefferies raised the firm’s price target on Merck (MRK) to $149 from $148 and keeps a Buy rating on the shares after subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy available for intravenous use as Keytruda, hit both primary endpoints in the pivotal Phase 3 MK-3475A-D77 trial. This is “an important win,” as Merck should be able to bridge approval for all IV solid tumor indications in U.S. with this data, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck ‘linked’ to takeover bid for Incyte, Sky News says
- Merck raises quarterly dividend to 81c from 77c per share
- Walmart higher, Lowe’s lower after earnings: Morning Buzz
- Merck announces ‘positive’ results from Phase 3 MK-3475A-D77 trial
- Merck receives CHMP opinion recommending approval of Keytruda
Questions or Comments about the article? Write to editor@tipranks.com